EcoR1 Capital LLC is a fundamental biotechnology-focused investment advisory firm. Based in San Francisco, EcoR1 evaluates and selects extraordinary biotechnology companies that are pursuing the highest quality science and demonstrate strong business fundamentals.
Like the EcoR1 restriction enzyme which helped to transform the biomedical field, EcoR1 seeks to help move medical research forward through investments into compelling biotech companies that are developing promising new solutions for untreated diseases.
We nurture lasting relationships.
We expand the possibilities of science.
We are committed to innovation.
Advancements in biotech are happening at a breakneck pace, and EcoR1 has the drive and vision to help patients with the most innovative science.
EcoR1 seeks to move medical research forward through thoughtful investments that are evaluated for scientific merit and business case.
Advancements in the biotech industry affect the lives of many. EcoR1 is committed to playing a role in finding answers for unmet medical needs.
EcoR1 identifies gutsy companies that have committed management and the potential to create value over and over again.
The EcoR1 team shepherds great drugs and great people over the peaks and valleys of drug discovery and development. Learn more about our leadership team.
FOUNDER AND MANAGING DIRECTOR
Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital LLC, a biotech-focused investment advisory firm. With 15 years of experience in investing and consulting, Mr. Nodelman has expertise in all aspects of investment management and deep roots in the biotech and scientific communities. Before founding EcoR1, Mr. Nodelman was a Portfolio Manager at BVF Partners, one of biotech’s first dedicated hedge funds. During his 11 years with BVF, Mr. Nodelman’s responsibilities spanned the entire investment process, from opportunity generation and due diligence to portfolio management and trading. Mr. Nodelman began his career in strategic consulting and organizational management at Mercer Management Consulting (now Oliver Wyman), where he worked with senior management from companies in a variety of industries to develop and implement long-term strategy and build shareholder value. Mr. Nodelman has a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.
CHIEF OPERATING OFFICER
AND CHIEF COMPLIANCE OFFICER
Ms. Marriott is the Chief Operating Officer and Chief Compliance Officer for EcoR1 Capital LLC, where she is responsible for regulatory and compliance issues. Ms. Marriott has experience working across the diverse areas of civil and criminal litigation. Most recently, Ms. Marriott served as a Deputy District Attorney in Solano County, California, where she tried approximately 30 cases to a jury and 10 cases to the bench. Prior to serving as a prosecutor, Ms. Marriott practiced at Orrick, Herrington & Sutcliffe LLP in San Francisco for six years. While there, Ms. Marriott handled breach-of-contract disputes, business tort claims, public pensions, employment and appellate advocacy, as well as white-collar criminal defense. Ms. Marriott previously completed a clerkship on the federal Court of Appeals for the Tenth Circuit. Ms. Marriott holds a law degree from the University of California, Berkeley, and a Bachelor of Arts degree from Amherst College.
DIRECTOR OF RESEARCH
Joseph Sum has spent the past eight years hunting for promising investments that may lead to solutions for devastating diseases. As the Director of Research at EcoR1 Capital LLC, Mr. Sum identifies and assesses opportunities to fund talented management teams in pursuit of novel therapeutic drugs and technologies. He was previously a biotech specialist at a $15B asset management firm, and worked as an Analyst for BVF Partners, where he led the successful spin off of Ziarco Pharma from Pfizer. Mr. Sum serves on the board of the New York-based Breast Cancer Task Force, which provides early cancer detection and treatment services to patients without health insurance, and has served on the boards of Ziarco Pharma and Airmid, Inc. He has Bachelor of Science degrees in Chemical Engineering and Materials Engineering from the University of California, Berkeley, and is a CFA Charterholder.
Caroline Stout specializes in operational and scientific analysis at EcoR1 Capital LLC. In her role as an EcoR1 Analyst, Ms. Stout informs the fund’s investment decisions by assessing clinical data and corporate insights to gain broad insights into biotechnology companies, markets and emerging science. She previously worked as an Investment Banking Analyst at Credit Suisse in New York, performing due diligence and financial valuation analysis for healthcare companies. She has experience working on a range of transactions in the healthcare and biotechnology sectors, including multi-billion dollar leveraged buyouts, initial public offerings and follow-on equity raises. Ms. Stout graduated magna cum laude from Georgetown University with a Bachelor of Arts in Economics, a Pre-Medical concentration, and Cognitive Science minor.
Mr. Platshon joined EcoR1 Capital, LLC in October 2015 after spending a year at Aquilo Partners, a boutique life sciences investment bank. Alongside Ms. Stout, Mr. Platshon serves as an analyst and is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. At Aquilo, Mr. Platshon prepared valuation materials and performed due diligence on M&A, licensing, and private placement transactions in the biotech, pharmaceutical and tools & diagnostics sector. Mr. Platshon holds a Bachelor of Science in Bioengineering from Stanford University, and was advised by Karl Deisseroth, the inventor of optogenetics and CLARITY, two breakthrough neuroscience technologies.
DIRECTOR OF PARTNER RELATIONS
Ms. McWilliams joined EcoR1 Capital, LLC to oversee the firm’s partner relations. Ms. McWilliams assumed this role in May 2016 after spending six and a half years as a Managing Director of Capital Introductions at BTIG, LLC, a privately owned boutique broker dealer. AT BTIG, her responsibilities included building and maintaining institutional investor relationships in the South, MidWest, and Western US regions. Prior to BTIG, Ms. McWilliams spent two and a half years with UBS’s Prime Brokerage division in the Dallas branch. She began her career as a real estate investment analyst focused on student housing assets on collegiate campuses. Ms. McWilliams received her BBA in Finance from the McCombs Business School at the University of Texas – Austin.
Mr. Sanon joined EcoR1 Capital, LLC as an intern in June 2017 and joined the team on a full time basis in August 2017 as a junior analyst. He is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. Previously, Mr. Sanon spent a summer in investment banking at Jefferies, where he prepared valuation and marketing materials and performed due diligence for companies across several sectors, including healthcare. He graduated from McGill University with a major in finance, as well as minors in life sciences and North American studies.
EcoR1 Capital, LLC
409 Illinois Street
San Francisco, CA 94158
Don't have an account with EcoR1?